{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:42:51Z","timestamp":1791517371504,"version":"4.3.4"},"publisher-location":"Cham","reference-count":61,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783032211064","type":"print"},{"value":"9783032211071","type":"electronic"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1007\/7854_2024_534","type":"book-chapter","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T11:05:50Z","timestamp":1729595150000},"page":"241-270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Anxiety and Affective Symptoms Related to the Use of Classic Psychedelics: A Systematic Review"],"prefix":"10.1007","author":[{"given":"Grace","family":"Viljoen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Betzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"issue":"12","key":"534_CR1","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1176\/appi.ajp.22010073","volume":"179","author":"G Barber","year":"2022","unstructured":"Barber G, Nemeroff CB, Siegel S (2022) A case of prolonged mania, psychosis, and severe depression after psilocybin use: implications of increased psychedelic drug availability. Am J Psychiatry 179(12):892\u2013896","journal-title":"Am J Psychiatry"},{"issue":"12","key":"534_CR2","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1177\/0269881116678781","volume":"30","author":"FS Barrett","year":"2016","unstructured":"Barrett FS, Bradstreet MP, Leoutsakos JMS, Johnson MW, Griffiths RR (2016) The challenging experience questionnaire: characterization of challenging experiences with psilocybin mushrooms. J Psychopharmacol 30(12):1279\u20131295","journal-title":"J Psychopharmacol"},{"issue":"6174","key":"534_CR3","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1136\/bmj.1.6174.1319","volume":"1","author":"C Benjamin","year":"1979","unstructured":"Benjamin C (1979) Persistent psychiatric symptoms after eating psilocybin mushrooms. Br Med J 1(6174):1319","journal-title":"Br Med J"},{"issue":"10","key":"534_CR4","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.biopsych.2019.05.019","volume":"86","author":"AK Bershad","year":"2019","unstructured":"Bershad AK, Schepers ST, Bremmer MP, Lee R, de Wit H (2019) Acute subjective and behavioral effects of microdoses of lysergic acid diethylamide in healthy human volunteers. Biol Psychiatry 86(10):792\u2013800","journal-title":"Biol Psychiatry"},{"issue":"5","key":"534_CR5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/00045391-199705000-00008","volume":"4","author":"K Blaho","year":"1997","unstructured":"Blaho K, Merigian K, Winbery S, Geraci SA, Smartt C (1997) Clinical pharmacology of lysergic acid diethylamide: case reports and review of the treatment of intoxication. Am J Ther 4(5):211","journal-title":"Am J Ther"},{"key":"534_CR6","doi-asserted-by":"crossref","unstructured":"Boer AP, Sipprelle CN (1969) Induced anxiety in the treatment for LSD effects. Psychother Psychosom:108\u2013113","DOI":"10.1159\/000286016"},{"issue":"10","key":"534_CR7","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","volume":"79","author":"MP Bogenschutz","year":"2022","unstructured":"Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E et al (2022) Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry 79(10):953\u2013962","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"534_CR8","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.janxdis.2006.09.014","volume":"21","author":"MO Bonn-Miller","year":"2007","unstructured":"Bonn-Miller MO, Bernstein A, Sachs-Ericsson N, Schmidt NB, Zvolensky MJ (2007) Associations between psychedelic use, abuse, and dependence and lifetime panic attack history in a representative sample. J Anxiety Disord 21(5):730\u2013741","journal-title":"J Anxiety Disord"},{"issue":"1","key":"534_CR9","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1038\/s41598-024-53188-9","volume":"14","author":"JJ Breeksema","year":"2024","unstructured":"Breeksema JJ, Niemeijer A, Krediet E, Karsten T, Kamphuis J, Vermetten E et al (2024) Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study. Sci Rep 14(1):2929","journal-title":"Sci Rep"},{"issue":"4","key":"534_CR10","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1080\/02791072.2017.1344898","volume":"49","author":"T Brown","year":"2017","unstructured":"Brown T, Shao W, Ayub S, Chong D, Cornelius C (2017) A physician\u2019s attempt to self-medicate bipolar depression with N, N-dimethyltryptamine (DMT). J Psychoactive Drugs 49(4):294\u2013296","journal-title":"J Psychoactive Drugs"},{"issue":"1","key":"534_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1037\/int0000109","volume":"29","author":"LA Brown","year":"2019","unstructured":"Brown LA, Zandberg LJ, Foa EB (2019) Mechanisms of change in prolonged exposure therapy for PTSD: implications for clinical practice. J Psychother Integr 29(1):6","journal-title":"J Psychother Integr"},{"issue":"12","key":"534_CR12","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1177\/0269881116662634","volume":"30","author":"TM Carbonaro","year":"2016","unstructured":"Carbonaro TM, Bradstreet MP, Barrett FS, MacLean KA, Jesse R, Johnson MW, Griffiths RR (2016) Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. J Psychopharmacol 30(12):1268\u20131278","journal-title":"J Psychopharmacol"},{"issue":"7","key":"534_CR13","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M et al (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3(7):619\u2013627","journal-title":"Lancet Psychiatry"},{"key":"534_CR14","unstructured":"Critical Appraisal Skills Programme (2018) CASP (Cohort studies Checklist)"},{"issue":"10","key":"534_CR15","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1038\/s41386-022-01344-y","volume":"47","author":"DC D\u2019Souza","year":"2022","unstructured":"D\u2019Souza DC, Syed SA, Flynn LT, Safi-Aghdam H, Cozzi NV, Ranganathan M (2022) Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder. Neuropsychopharmacology 47(10):1854\u20131862","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"534_CR16","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2021","unstructured":"Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW et al (2021) Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry 78(5):481\u2013489","journal-title":"JAMA Psychiatry"},{"issue":"27","key":"534_CR17","doi-asserted-by":"publisher","first-page":"iii","DOI":"10.3310\/hta7270","volume":"7","author":"JJ Deeks","year":"2003","unstructured":"Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F et al (2003) Evaluating non-randomised intervention studies. Health Technol Assess 7(27):iii\u2013x. 1\u2013173","journal-title":"Health Technol Assess"},{"key":"534_CR18","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (2021) European Web survey on drugs 2021: top level findings, 21 EU countries and Switzerland"},{"issue":"7","key":"534_CR19","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","volume":"202","author":"P Gasser","year":"2014","unstructured":"Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, Brenneisen R (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 202(7):513\u2013520","journal-title":"J Nerv Ment Dis"},{"issue":"3","key":"534_CR20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s13318-023-00822-y","volume":"48","author":"M Good","year":"2023","unstructured":"Good M, Joel Z, Benway T, Routledge C, Timmermann C, Erritzoe D et al (2023) Pharmacokinetics of N, N-dimethyltryptamine in humans. Eur J Drug Metab Pharmacokinet 48(3):311\u2013327","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"18","key":"534_CR21","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC et al (2022) Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med 387(18):1637\u20131648","journal-title":"N Engl J Med"},{"issue":"10","key":"534_CR22","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1038\/s41386-023-01648-7","volume":"48","author":"GM Goodwin","year":"2023","unstructured":"Goodwin GM, Croal M, Feifel D, Kelly JR, Marwood L, Mistry S et al (2023) Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology 48(10):1492\u20131499","journal-title":"Neuropsychopharmacology"},{"key":"534_CR23","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","volume":"187","author":"RR Griffiths","year":"2006","unstructured":"Griffiths RR, Richards WA, McCann U, Jesse R (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 187:268\u2013283","journal-title":"Psychopharmacology (Berl)"},{"key":"534_CR24","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","volume":"218","author":"RR Griffiths","year":"2011","unstructured":"Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R (2011) Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl) 218:649\u2013665","journal-title":"Psychopharmacology (Berl)"},{"issue":"12","key":"534_CR25","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD et al (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol 30(12):1181\u20131197","journal-title":"J Psychopharmacol"},{"key":"534_CR26","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3389\/fphar.2018.00897","volume":"9","author":"EC Haijen","year":"2018","unstructured":"Haijen EC, Kaelen M, Roseman L, Timmermann C, Kettner H, Russ S et al (2018) Predicting responses to psychedelics: a prospective study. Front Pharmacol 9:897","journal-title":"Front Pharmacol"},{"key":"534_CR27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","volume":"172","author":"F Hasler","year":"2004","unstructured":"Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX (2004) Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose\u2013effect study. Psychopharmacology (Berl) 172:145\u2013156","journal-title":"Psychopharmacology (Berl)"},{"issue":"7","key":"534_CR28","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/bdi.13095","volume":"23","author":"HM Hendin","year":"2021","unstructured":"Hendin HM, Penn AD (2021) An episode of mania following self-reported ingestion of psilocybin mushrooms in a woman previously not diagnosed with bipolar disorder: a case report. Bipolar Disord 23(7):733\u2013735","journal-title":"Bipolar Disord"},{"issue":"3","key":"534_CR29","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41386-020-00883-6","volume":"46","author":"F Holze","year":"2021","unstructured":"Holze F, Vizeli P, Ley L, M\u00fcller F, Dolder P, Stocker M et al (2021) Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology 46(3):537\u2013544","journal-title":"Neuropsychopharmacology"},{"key":"534_CR30","unstructured":"Holze F, Caluori TV, Vizeli P, Liechti ME (2022a) Safety pharmacology of acute LSD administration in healthy subjects. Psychopharmacology (Berl):1\u201313"},{"issue":"6","key":"534_CR31","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41386-022-01297-2","volume":"47","author":"F Holze","year":"2022","unstructured":"Holze F, Ley L, M\u00fcller F, Becker AM, Straumann I, Vizeli P et al (2022b) Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology 47(6):1180\u20131187","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"534_CR32","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","volume":"93","author":"F Holze","year":"2023","unstructured":"Holze F, Gasser P, M\u00fcller F, Dolder PC, Liechti ME (2023) Lysergic acid diethylamide\u2013assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study. Biol Psychiatry 93(3):215\u2013223","journal-title":"Biol Psychiatry"},{"issue":"8","key":"534_CR33","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1177\/02698811221099650","volume":"36","author":"EI Kopra","year":"2022","unstructured":"Kopra EI, Ferris JA, Rucker JJ, McClure B, Young AH, Copeland CS, Winstock AR (2022) Adverse experiences resulting in emergency medical treatment seeking following the use of lysergic acid diethylamide (LSD). J Psychopharmacol 36(8):956\u2013964","journal-title":"J Psychopharmacol"},{"issue":"11","key":"534_CR34","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1176\/ajp.138.11.1508","volume":"138","author":"CR Lake","year":"1981","unstructured":"Lake CR, Stirba AL, Kinneman RE Jr, Carlson B, Holloway HC (1981) Mania associated with LSD ingestion. Am J Psychiatry 138(11):1508\u20131509","journal-title":"Am J Psychiatry"},{"issue":"2","key":"534_CR35","first-page":"100","volume":"39","author":"AG Lerner","year":"2002","unstructured":"Lerner AG, Shufman E, Kodesh A, Kretzmer G, Sigal M (2002) LSD-induced hallucinogen persisting perception disorder with depressive features treated with reboxetine: case report. Isr J Psychiatry 39(2):100","journal-title":"Isr J Psychiatry"},{"issue":"3","key":"534_CR36","doi-asserted-by":"publisher","first-page":"e0300501","DOI":"10.1371\/journal.pone.0300501","volume":"19","author":"AW Levin","year":"2024","unstructured":"Levin AW, Lancelotta R, Sepeda ND, Gukasyan N, Nayak S, Wagener TL et al (2024) The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder. PLoS One 19(3):e0300501","journal-title":"PLoS One"},{"issue":"10","key":"534_CR37","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.3390\/molecules26102948","volume":"26","author":"H Lowe","year":"2021","unstructured":"Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A et al (2021) The therapeutic potential of psilocybin. Molecules 26(10):2948","journal-title":"Molecules"},{"issue":"1","key":"534_CR38","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1177\/02698811231196877","volume":"38","author":"LX Luan","year":"2024","unstructured":"Luan LX, Eckern\u00e4s E, Ashton M, Rosas FE, Uthaug MV, Bartha A et al (2024) Psychological and physiological effects of extended DMT. J Psychopharmacol 38(1):56\u201367","journal-title":"J Psychopharmacol"},{"issue":"3","key":"534_CR39","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/mp.2014.24","volume":"20","author":"Y Ma","year":"2015","unstructured":"Ma Y (2015) Neuropsychological mechanism underlying antidepressant effect: a systematic meta-analysis. Mol Psychiatry 20(3):311\u2013319","journal-title":"Mol Psychiatry"},{"key":"534_CR40","doi-asserted-by":"publisher","first-page":"100104","DOI":"10.1016\/j.nsa.2022.100104","volume":"1","author":"LJ Mertens","year":"2022","unstructured":"Mertens LJ, Koslowski M, Betzler F, Evens R, Gilles M, Jungaberle A et al (2022) Methodological challenges in psychedelic drug trials: efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE)\u2013rationale and study design. Neurosci Appl 1:100104","journal-title":"Neurosci Appl"},{"key":"534_CR41","doi-asserted-by":"crossref","unstructured":"Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R et al (2020) Chapter 7: systematic reviews of etiology and risk. JBI Manual Evid Synth 10","DOI":"10.46658\/JBIRM-17-06"},{"key":"534_CR42","doi-asserted-by":"publisher","first-page":"788155","DOI":"10.3389\/fphar.2021.788155","volume":"12","author":"R Murphy","year":"2022","unstructured":"Murphy R, Kettner H, Zeifman R, Giribaldi B, Kartner L, Martell J et al (2022) Therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression. Front Pharmacol 12:788155","journal-title":"Front Pharmacol"},{"key":"534_CR43","doi-asserted-by":"publisher","first-page":"1199642","DOI":"10.3389\/fpsyt.2023.1199642","volume":"14","author":"SM Nayak","year":"2023","unstructured":"Nayak SM, Jackson H, Sepeda ND, Mathai DS, So S, Yaffe A et al (2023) Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey. Front Psych 14:1199642","journal-title":"Front Psych"},{"key":"534_CR45","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372","DOI":"10.1136\/bmj.n71"},{"key":"534_CR46","doi-asserted-by":"crossref","unstructured":"Palitsky R, Kaplan DM, Perna J, Bosshardt Z, Maples-Keller JL, Levin-Aspenson HF et al (2024) A framework for assessment of adverse events occurring in psychedelic assisted therapies. J Psychopharmacol","DOI":"10.31234\/osf.io\/h2wfy"},{"issue":"4","key":"534_CR47","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/WNF.0000000000000078","volume":"38","author":"NE Paterson","year":"2015","unstructured":"Paterson NE, Darby WC, Sandhu PS (2015) N, N-dimethyltryptamine\u2013induced psychosis. Clin Neuropharmacol 38(4):141\u2013143","journal-title":"Clin Neuropharmacol"},{"key":"534_CR48","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s002130000606","volume":"154","author":"J Riba","year":"2001","unstructured":"Riba J, Rodr\u00edguez-Fornells A, Urbano G, Morte A, Antonijoan R, Montero M et al (2001) Subjective effects and tolerability of the south American psychoactive beverage Ayahuasca in healthy volunteers. Psychopharmacology (Berl) 154:85\u201395","journal-title":"Psychopharmacology (Berl)"},{"issue":"9","key":"534_CR49","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1177\/0269881119855974","volume":"33","author":"L Roseman","year":"2019","unstructured":"Roseman L, Haijen E, Idialu-Ikato K, Kaelen M, Watts R, Carhart-Harris R (2019) Emotional breakthrough and psychedelics: validation of the emotional breakthrough inventory. J Psychopharmacol 33(9):1076\u20131087","journal-title":"J Psychopharmacol"},{"issue":"3","key":"534_CR50","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/ADM.0000000000000734","volume":"15","author":"DS Rubin-Kahana","year":"2021","unstructured":"Rubin-Kahana DS, Hassan AN, Le Foll B (2021) Posttraumatic stress disorder after a psychedelic experience, a case report. J Addict Med 15(3):248\u2013251","journal-title":"J Addict Med"},{"issue":"1","key":"534_CR51","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1177\/02698811211064720","volume":"36","author":"JJ Rucker","year":"2022","unstructured":"Rucker JJ, Marwood L, Ajantaival RLJ, Bird C, Eriksson H, Harrison J et al (2022) The effects of psilocybin on cognitive and emotional functions in healthy participants: results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation. J Psychopharmacol 36(1):114\u2013125","journal-title":"J Psychopharmacol"},{"key":"534_CR52","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jpsychires.2023.03.031","volume":"161","author":"FR Schneier","year":"2023","unstructured":"Schneier FR, Feusner J, Wheaton MG, Gomez GJ, Cornejo G, Naraindas AM, Hellerstein DJ (2023) Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder. J Psychiatr Res 161:364\u2013370","journal-title":"J Psychiatr Res"},{"key":"534_CR53","doi-asserted-by":"crossref","unstructured":"Simonsson O, Mosing MA, Osika W, Ull\u00e9n F, Larsson H, Lu Y, Wesseldijk LW (2024) Adolescent psychedelic use and psychotic or manic symptoms. JAMA Psychiatry","DOI":"10.1001\/jamapsychiatry.2024.0047"},{"issue":"7","key":"534_CR54","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1177\/02698811231154852","volume":"37","author":"J Sloshower","year":"2023","unstructured":"Sloshower J, Skosnik PD, Safi-Aghdam H, Pathania S, Syed S, Pittman B, D\u2019Souza DC (2023) Psilocybin-assisted therapy for major depressive disorder: an exploratory placebo-controlled, fixed-order trial. J Psychopharmacol 37(7):698\u2013706","journal-title":"J Psychopharmacol"},{"key":"534_CR55","doi-asserted-by":"crossref","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366","DOI":"10.1136\/bmj.l4898"},{"issue":"2","key":"534_CR56","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1001\/archpsyc.1994.03950020022002","volume":"51","author":"RJ Strassman","year":"1994","unstructured":"Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner R (1994) Dose-response study of N,N-dimethyltryptamine in humans: II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 51(2):98\u2013108","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"534_CR57","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1177\/0269881110382466","volume":"25","author":"E Studerus","year":"2011","unstructured":"Studerus E, Kometer M, Hasler F, Vollenweider FX (2011) Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol 25(11):1434\u20131452","journal-title":"J Psychopharmacol"},{"issue":"8","key":"534_CR58","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1097\/NMD.0000000000001489","volume":"210","author":"M Suleiman","year":"2022","unstructured":"Suleiman M, Basu A, Belal S, Jacob T (2022) From mushrooms to myolysis: a case of rhabdo in psilocybin-induced mood and psychotic disorder. J Nerv Ment Dis 210(8):638\u2013639","journal-title":"J Nerv Ment Dis"},{"key":"534_CR59","doi-asserted-by":"publisher","first-page":"344412","DOI":"10.3389\/fphar.2018.00172","volume":"9","author":"LR Swanson","year":"2018","unstructured":"Swanson LR (2018) Unifying theories of psychedelic drug effects. Front Pharmacol 9:344412","journal-title":"Front Pharmacol"},{"issue":"1","key":"534_CR60","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41398-023-02477-4","volume":"13","author":"SB Vogt","year":"2023","unstructured":"Vogt SB, Ley L, Erne L, Straumann I, Becker AM, Klaiber A et al (2023) Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants. Transl Psychiatry 13(1):172","journal-title":"Transl Psychiatry"},{"key":"534_CR61","first-page":"501786","volume":"11","author":"M Wolff","year":"2020","unstructured":"Wolff M, Evens R, Mertens LJ, Koslowski M, Betzler F, Gr\u00fcnder G, Jungaberle H (2020) Learning to let go: a cognitive-behavioral model of how psychedelic therapy promotes acceptance. Front Psych 11:501786","journal-title":"Front Psych"},{"key":"534_CR62","doi-asserted-by":"publisher","first-page":"107343","DOI":"10.1016\/j.addbeh.2022.107343","volume":"132","author":"KH Yang","year":"2022","unstructured":"Yang KH, Han BH, Palamar JJ (2022) Past-year hallucinogen use in relation to psychological distress, depression, and suicidality among US adults. Addict Behav 132:107343","journal-title":"Addict Behav"}],"container-title":["Current Topics in Behavioral Neurosciences","Psychedelic Harm Reduction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/7854_2024_534","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T19:03:24Z","timestamp":1781204604000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/7854_2024_534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9783032211064","9783032211071"],"references-count":61,"URL":"https:\/\/doi.org\/10.1007\/7854_2024_534","relation":{},"ISSN":["1866-3370","1866-3389"],"issn-type":[{"value":"1866-3370","type":"print"},{"value":"1866-3389","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"23 October 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}